Idiopathic Pulmonary Fibrosis

Ofev Slows Idiopathic Pulmonary Fibrosis Progression Long-Term

By September 17, 2018

The primary objective was to characterize the long-term safety and tolerability of Ofev in patients with IPF; efficacy endpoints included annual rate of decline in forced vital capacity (FVC) calculated over 192 weeks.

FDA Fast-Tracks Pamrevlumab for Idiopathic Pulmonary Fibrosis

By September 12, 2018

The FDA's designation was based on data from a Phase 2 placebo-controlled trial that demonstrated pamrevlumab could potentially address an unmet medical need for this condition.

Anti-Fibrotic Drug Gets Orphan Drug Status for Idiopathic Pulmonary Fibrosis

By August 07, 2018

Targeting TGF-β signaling in a tissue-specific manner allows the drug to modulate the fibrotic cascade with maximum clinical effects while avoiding adverse events

Recombinant human pentraxin 2 slows the decline in lung function in idiopathic pulmonary fibrosis

June 07, 2018

The use of recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis.

Treatment for Idiopathic Pulmonary Fibrosis Gets Orphan Drug Designation

By April 10, 2018

RP5063 is a new chemical entity with a novel mechanism of multimodal modulation of serotonin and dopamine signaling pathways.

Sirolimus May Be Beneficial in DIPNECH Syndrome

April 10, 2018

The patients began treatment with oral sirolimus; after 1 year of treatment, there was improvement in exertional dyspnea in all 3 patients.

Cluster of Idiopathic Pulmonary Fibrosis Cases ID'd Among Dentists

By March 14, 2018

Some substances used while conducting these tasks contained silica, polyvinyl siloxane, alginate, and other compounds with known or potential respiratory toxicity.